
    
      This is a prospective, interventional, non-randomized, multi-center trial, with each site
      following a common protocol in Japan. A maximum of 20 subjects will be implanted at a maximum
      of 10 sites in Japan. The trial will include male and female patients of legal age to provide
      informed consent in Japan, requiring replacement for a diseased, damaged, or malfunctioning
      native or prosthetic aortic valve. Patients will be followed and assessed after implant for
      up to 5 years.
    
  